Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy-Reference-Cited by-同舟云学术

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy

Published:2014-11-17 Issue:2 Volume:88 Page:101-109
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Mathis Stéphanie¹²,Chapuis Nicolas¹²,Borgeot Jessica³,Maynadié Marc³,Fontenay Michaela¹²,Béné Marie-Christine⁴,Guy Julien³,Bardet Valérie¹²

Affiliation:

1. Service d'Hématologie Biologique; Hôpitaux Universitaires Paris Centre Cochin; Paris France

2. Inserm U1016; Université Paris Descartes, Hôpitaux Universitaires Paris Centre Cochin; Paris France

3. Service d'Hématologie Biologique; CHU; Dijon France

4. Service d'Hématologie Biologique; CHU; Nantes France

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Reference32 articles.

1. Multiple myeloma;Kyle;N Engl J Med,2004

2. A report of the International Myeloma Working Group;Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders;Br J Haematol,2003

3. Beyond the CRAB symptoms: A study of presenting clinical manifestations of multiple myeloma;Talamo;Clin Lymphoma Myeloma Leuk,2010

4. Association of response endpoints with survival outcomes in multiple myeloma;Lonial;Leukemia,2014

5. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma;Kyle;Leukemia,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium;Diagnostics;2021-10-11

2. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges;Cancers;2021-09-12

3. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors;Cytometry Part B: Clinical Cytometry;2020-10-28

4. Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches;Oncohematology;2020-04-19

5. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies;Cytometry Part B: Clinical Cytometry;2018-01-19